An interesting study from 2019 analyzed AraC resistance in AML patient-derived xenografts and targeted mitochondrial metabolism via the CD36-mitochondrial FA β-oxidation and oxidative phosphorylation 51. This evidence concerns the gene CD36 and acute myeloid leukemia.